EcoDrugPlus

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSSTUG00000019802
Gene Symbol: HTR3B
1 Cross references
170 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSTUG00000012413
Gene Symbol: HTR4
3 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSSTUG00000032302
Gene Symbol: HTR4
3 Cross references
193 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSTUG00000006259
Gene Symbol: HTR5A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 5a

Ensembl ID : ENSSTUG00000013284
Gene Symbol: HTR5A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSSTUG00000028123
Gene Symbol: HTR7
3 Cross references
147 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSSTUG00000001018
Gene Symbol: LOC115148465
2 Cross references
190 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSSTUG00000049293
Gene Symbol: LOC115200870
2 Cross references
190 Possible Orthologues:

5-Hydroxytryptamine Receptor 7-Like

Ensembl ID : ENSSTUG00000021310
Gene Symbol: LOC115148517
2 Cross references
147 Possible Orthologues:

60s Acidic Ribosomal Protein P0

Ensembl ID : ENSSTUG00000005415
Gene Symbol: LOC115208043
3 Cross references
393 Possible Orthologues:

60s Acidic Ribosomal Protein P0-Like

Ensembl ID : ENSSTUG00000007444
Gene Symbol: LOC115150384
3 Cross references
392 Possible Orthologues:

60s Acidic Ribosomal Protein P1-Like

Ensembl ID : ENSSTUG00000047603
Gene Symbol: LOC115174066
3 Cross references
374 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).